Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016

登录注册会员服务联系我们

Uptake of Antifibrotics for Patients with Idiopathic Pulmonary Fibrosis: 2016–2022

Published:2024-01 Issue:1 Volume:21 Page:170-173
ISSN:2329-6933
Container-title:Annals of the American Thoracic Society
language:en
Short-container-title:Annals ATS

Author:

Shankar Divya A.¹^ORCID,Hawkins Finn¹^ORCID,Alysandratos Konstantinos-Dionysios¹^ORCID,Wilson Kevin C.¹^ORCID,Walkey Allan J.¹^ORCID,Bosch Nicholas A.¹^ORCID,Law Anica C.¹^ORCID

Affiliation:

1. Boston University School of MedicineBoston, Massachusetts

Funder

National Heart, Lung, and Blood Institute

Publisher

American Thoracic Society

Subject

Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1513/AnnalsATS.202308-697RL

Reference17 articles.

1. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

2. Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go

3. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

4. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

5. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP